Betting Big on Bispecifics
The Next Wave of Bispecific Antibodies & Antibody‑Mediated Vaccines
TL;DR:
What’s changing: We’re moving from short-term tumor attack to longer-lasting immune control.
One antibody that blocks an immune brake and tamps down tumor blood vessels (PD-1/PD-L1 × VEGF) looks like a future backbone in first-line care.
Some drugs activate the body’s “teacher cells” (dendritic cells) right inside tumors so T cells learn better and stay active longer.
Antibodies that act like vaccines: AMVs deliver both an antigen and the right “go” signal to teacher cells, aiming for durable protection with fewer doses.
Multi-billion-dollar deals (BMS–BioNTech, Pfizer–3SBio, Merck–LaNova) show how hard pharma is betting on these one-molecule combos and multispecific platforms.
Where this could land first: Lung cancer today; pressure is building to expand into breast, liver, colorectal, and melanoma if safety and durability hold up.
Why patients might care: Fewer infusions, deeper responses, and longer control, if the science translates.
What could go wrong: Side effects from hitting two targets at once, tricky manufacturing, crowded races where “me-too” drugs blend together, and the need to beat standard two-drug regimens head-to-head.
What to watch: Clear survival gains (not just tumor shrinkage), cleaner safety, smart patient-selection tests, first approvals for PD-(L)1×VEGF bispecifics, early human data from dendritic-cell activators, and AMVs proving they can create lasting immune memory.
Bispecific antibodies started as an experiment: scientists fused two antibody fragments together to see if they could bind two targets at once. Those early molecules were clumsy, but they hinted at a new way of using the immune system. Fast‑forward to today, and bispecifics are a major pillar of immunotherapy. Catumaxomab, approved in 2009 for malignant ascites, was the first to show that one antibody could grab two different proteins, EpCAM on tumor cells and CD3 on T cells, to direct an immune attack. Blinatumomab then became the first FDA‑approved bispecific for acute lymphoblastic leukemia (ALL), proving the concept of a T‑cell engager in leukemia. Since 2021, the pace of approvals has only quickened; by mid‑2025, more than a dozen bispecifics were on the market in the U.S. or Europe, and hundreds more were in clinical development.
The clinical results are impressive. In minimal residual disease–negative B‑cell precursor ALL, adding blinatumomab to consolidation chemotherapy boosted three‑year overall survival from 68 % to 85 %, though neurologic events were more common with the combination. Mosunetuzumab delivered a 78 % overall response rate and a 60 % complete response in relapsed or refractory follicular lymphoma. Epcoritamab, a subcutaneous CD20×CD3 bispecific, showed a 63 % overall response and 40 % complete response at two years in diffuse large B‑cell lymphoma, with about 28 % progression‑free survival and 45 % overall survival. Multiple myeloma, once a graveyard for heavily pretreated patients, now sees 60–70 % response rates with teclistamab, talquetamab and elranatamab. A trispecific antibody targeting CD38, BCMA and CD3 has delivered a 79 % response and 30 % complete response. On the solid‑tumor front, amivantamab (EGFR×MET) has expanded options for non‑small‑cell lung cancer, and tebentafusp has improved survival in uveal melanoma. Bispecifics have even made inroads beyond oncology: faricimab treats neovascular eye disease, and emicizumab revolutionized hemophilia therapy.
There are, however, real limits. Many tumor antigens are also found on healthy tissues, leading to side effects like hypogammaglobulinemia, taste changes or nail disorders. Tumors can shed or down‑regulate antigens, and T cells can burn out when overstimulated. Solid tumors are packed with suppressive cells and dense stroma that make it hard for immune cells to infiltrate. Some bispecifics require continuous infusion or complex dosing schedules, and producing these multi‑chain molecules reliably is still tricky.
The hottest area right now is PD‑(L)1×VEGF bispecifics. These antibodies block PD‑1/PD‑L1 while also neutralizing vascular endothelial growth factor. The biology is compelling: anti‑VEGF therapy normalizes the abnormal blood vessels that feed tumors, improving immune cell trafficking; PD‑1/PD‑L1 blockade reinvigorates exhausted T cells. Ivonescimab, developed by Akeso and Summit and licensed by BioNTech, is a prime example. In a phase‑III trial for PD‑L1‑positive lung cancer, it doubled progression‑free survival compared to pembrolizumab and halved the risk of progression or death. Roughly 30 % of patients experienced serious side effects like proteinuria and elevated liver enzymes. Even so, the data generated a gold rush. Bristol Myers Squibb and BioNTech signed an $11 billion co‑development deal for BNT327, with BMS paying $1.5 billion upfront, adding $2 billion in near‑term payments and promising up to $7.6 billion more in milestones. Pfizer paid $1.25 billion upfront for rights to SSGJ‑707, with another $4.8 billion in potential milestones and a $100 million equity investment. Merck spent $588 million upfront and could shell out up to $2.7 billion more to secure LaNova’s PD‑1×VEGF candidate. Collectively these deals say one thing: companies believe a dual‑mechanism, single‑molecule therapy could become a pan‑tumor backbone.
Behind the scenes, PD‑1×VEGF bispecifics exhibit fascinating cooperative binding. In some constructs, engaging VEGF increases PD‑1 affinity by about eighteenfold, and binding PD‑1 boosts VEGF affinity fourfold. Preclinical models suggest these drugs outperform separate antibodies because of this synergy. More than 1 000 patients have already been treated with BNT327 across lung and breast cancer trials, and multiple phase‑III studies are underway.
That said, the field is starting to pivot from simply redirecting T cells to orchestrating the immune synapse, the moment when dendritic cells present antigens to T cells and determine whether to activate them. Dendritic cells (DCs) are the conductors here. PD‑1×CD40 bispecifics take advantage of this by blocking PD‑1 on T cells while activating CD40 on DCs, but only when the antibody is tethered to PD‑1. Preclinical studies of YH008 (also known as NWY001) showed stronger tumor killing and fewer systemic cytokines compared to giving PD‑1 and CD40 antibodies separately. A phase‑I trial that started in January 2024 is now testing this idea in patients.
Other companies are trying similar approaches. Bispecifics that block PD‑L1 and activate CD40 show more powerful activation of dendritic cells and better tumor control in mice, while reducing the risk of systemic inflammation. Shattuck Labs built a CD47×CD40 bispecific that reprograms macrophages by blocking the “don’t‑eat‑me” signal (CD47) and delivering a CD40 stimulus; early trials produced dose‑dependent cytokine increases and stable disease in about 22 % of ovarian cancer patients.
Then there are bispecifics designed to physically bridge T cells and dendritic cells. PD‑1×CLEC9A constructs link PD‑1‑positive T cells with CLEC9A‑expressing dendritic cells, recreating the natural synapse and sparking robust cross‑priming. Preclinical work suggests they could overcome resistance to PD‑1 blockade. Others tether CD40 agonists to dendritic cell markers such as CD11c, DEC‑205 or CLEC9A, delivering co‑stimulation precisely where it’s needed and reducing systemic toxicity. Genmab and BioNTech’s DuoBody CD40×4‑1BB bispecific goes a step further, activating CD40 on dendritic cells and 4‑1BB on T cells only when both targets are engaged; early clinical data show enhanced dendritic cell maturation and T‑cell activation, and responses are even stronger when combined with PD‑1 blockade. An inventive “AcTakine” delivers type I interferon to CLEC9A‑positive DCs and PD‑L1‑positive tumor cells, reprogramming the tumor environment and clearing tumors in mice when combined with chemotherapy. Alligator Bioscience’s Neo‑X‑Prime platform clusters CD40‑positive dendritic cells with tumor antigens, turning tumors into their own vaccine factory and encouraging T‑cell memory.
What motivates these strategies? Research has shown that long‑term tumor control often depends on so‑called “immune triads”, clusters of CD8⁺ killer T cells, CD4⁺ helper T cells and dendritic cells working together. These clusters sometimes form tertiary lymphoid structures inside tumors, and their presence is linked to better responses to checkpoint inhibitors. By physically bringing T cells and dendritic cells together and providing co‑stimulation, bispecifics aim to recreate these structures in situ.
Vaccine approaches are also evolving. Therapeutic cancer vaccines have struggled for decades because tumors are heterogenous, suppressive microenvironments blunt immune responses, and early vaccines lacked the co‑stimulation needed to overcome tolerance. Today’s vaccines are different. Many deliver multiple antigens at once and are paired with checkpoint inhibitors, chemotherapy or radiation to release tumor antigens and make the tumor more immunogenic. The COVID‑19 mRNA vaccine success has rekindled interest in mRNA and neoantigen vaccines. Personalized mRNA vaccines for pancreatic cancer have already produced immune responses lasting three years. But even these may require repeat dosing.
That’s where antibody‑mediated vaccines (AMVs) come in. AMVs fuse an antibody “head” that binds CD40 on dendritic cells with a swappable antigen “tail.” This one‑molecule design delivers the antigen and a potent co‑stimulatory signal directly to dendritic cells. In a phase‑I HIV trial, an AMV generated immune responses that lasted about 80 weeks and were extended with a single low‑dose booster. EnnoDC’s HPV‑targeted AMV for oropharyngeal cancer produced robust CD4⁺ and CD8⁺ responses and early signs of tumor regression. By delivering antigen and co‑stimulation together, AMVs hope to overcome tolerance and trigger durable immunity. Challenges remain: CD40 agonism can cause systemic inflammation, solid tumors may still suppress responses, and picking the right antigen is crucial. But the idea that we could administer an immunotherapy that behaves like a vaccine, creating memory rather than requiring continuous dosing, is exciting.
The commercial landscape mirrors this scientific momentum. Bispecifics generated more than US$8.5 billion in revenue in 2023, up over 47 % from 2022, and analysts expect the market to grow from about US$9.8 billion in 2025 to US$22.4 billion by 2030. More than 800 bispecific candidates are in development across cancer, eye disease, autoimmunity and infectious disease. Big pharma is diversifying beyond oncology. Sanofi bought DR‑0201, a myeloid cell engager that binds Dectin‑1 on dendritic cells and CD20 on B cells, for $600 million upfront with up to $1.3 billion in milestones. By depleting pathogenic B cells, DR‑0201 could reset immune balance in diseases like lupus. Otsuka licensed a BCMA×CD3 bispecific from Harbour BioMed for autoimmune disorders, paying $47 million upfront and near‑term milestones. AbbVie invested in masked tumor‑activated bispecifics from Xilio, paying $52 million upfront and committing to up to $2.1 billion in options and milestones. A few months later, AbbVie paid $700 million upfront for a trispecific myeloma antibody with another $1.225 billion in potential payments. These deals illustrate how investors are betting on platform technologies that can spin out multiple bispecific or trispecific assets.
Even with all this enthusiasm, the road ahead isn’t straightforward. Manufacturing bispecifics involves pairing multiple heavy and light chains correctly and ensuring they stay stable, no small feat. Dual targeting raises the risk of cytokine release syndrome and off‑tumor toxicity. Regulators will require evidence that bispecifics outperform simple combination therapy; negative results from some PD‑(L)1 plus anti‑angiogenic combinations warn us not to assume synergy. With so many programs, competition is fierce and popular target pairs could become commoditized. Intellectual property can be fragile, and late‑stage deals could disappoint if clinical results don’t meet expectations.
The key signals to watch include tissue‑level proof that dendritic cells are maturing and antigens are spreading, biomarkers that guide patient selection, durability after treatment stops, scalable manufacturing and truly novel target combinations. Without these, another promising platform might join the long list of over‑hyped oncology strategies.
Bispecific antibodies have already improved survival in blood cancers and are beginning to impact solid tumors. The PD‑(L)1×VEGF craze shows how quickly enthusiasm and investment can swell, and how much depends on durable responses and manageable safety. The next decade will likely be about more than redirecting T cells. It will be about teaching the immune system to recognize and remember tumors. Multispecific antibodies that modulate the tumor microenvironment, dendritic‑cell‑targeting constructs that recreate the immune synapse, and antibody‑mediated vaccines that behave like long‑lasting vaccines could redefine cancer care. To get there, we’ll need rigorous science, thoughtful combinations, scalable production and a focus on genuine novelty. But if those pieces come together, orchestrating the immune synapse may become a cornerstone of immunotherapy in the years to come.